TFF Pharmaceuticals’ Scientific Consultant Robert O. Williams III Named to National Academy of Inventors

University of Texas at Austin professor named one of the National Academy of Inventors Fellows for 2019

AUSTIN, Texas–(BUSINESS WIRE)–Jan. 7, 2020–
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported that Robert O. (Bill) Williams III, Ph.D., its scientific consultant and inventor of the firm’s TFF technology, has been named one of the National Academy of Inventors Fellows for 2019, joining a list of 168 academic inventors from around the world..

Dr. Williams is the Professor and head of The University of Texas at Austin College of Pharmacy’s Division of Molecular Pharmaceutics and Drug Delivery. He is the only faculty member from UT Austin to be inducted into this year’s Fellows Program.

“This is a wonderful honor for a dedicated scientist, researcher and inventor,” said Glenn Mattes, President and CEO of TFF Pharmaceuticals. “Bill has been a great friend to the company and his seminal invention and development of Thin Film Freezing technology will make a significant difference in drug delivery to impact patient lives around the world.”

Dr. Williams is the Johnson and Johnson Centennial Chair. His research has devoted significant effort to enhance drug solubility and dissolution through particle engineering technologies, including thin film freezing and precipitation processes, and thermal processes. His patents broadly cover inhaled dry powder drug delivery systems made by thin film freezing technology.

A co-founder of several pharmaceutical companies, Dr. Williams was elected fellow of the American Association of Pharmaceutical Scientists (AAPS) in 2006 and fellow of the American Institute for Medical and Biological Engineering in 2008. He has published more than 400 peer-reviewed research articles, reviews, abstracts and book chapters, and he has co-edited two books in the fields of pharmaceutical technology and drug delivery, including “Formulating Poorly Water Soluble Drugs” (AAPSPRESS and Springer). He has been the editor-in-chief of AAPS PharmSciTech since 2014 and was editor-in-chief of Drug Development and Industrial Pharmacy (Taylor & Francis) from 2000 to 2014.

Williams will be formally inducted into the National Academy of Inventors Fellows program at the 2020 NAI Fellows Induction Ceremony on April 10, 2020.

About TFF Pharmaceuticals’ Thin Film Freezing technology platform

TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments, the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 39 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at


This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFF platform and its dry powder version of Voriconazole and Tacrolimus, and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform and (iii) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the on December 9, 2019. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Source: TFF Pharmaceuticals, Inc.


Glenn Mattes

President and CEO

TFF Pharmaceuticals, Inc


Kirk Coleman

Chief Financial Officer

TFF Pharmaceuticals, Inc.


Investor Relations and Media:

Paul Sagan